Haemonetics Corporation (NYSE:HAE) Receives Consensus Rating of “Moderate Buy” from Analysts

Haemonetics Corporation (NYSE:HAE) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $79.70.

HAE has been the topic of a number of research analyst reports. BTIG Research reissued a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research report on Friday, November 21st. Mizuho dropped their price objective on Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Citigroup decreased their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. JPMorgan Chase & Co. restated a “neutral” rating and set a $62.00 target price (down from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $90.00 price target on shares of Haemonetics in a research note on Friday, November 14th.

Haemonetics Stock Up 0.2%

Shares of HAE opened at $83.98 on Friday. The company’s 50-day moving average price is $61.83 and its 200 day moving average price is $63.84. Haemonetics has a 12-month low of $47.31 and a 12-month high of $85.23. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08. The firm has a market cap of $3.93 billion, a P/E ratio of 24.56, a price-to-earnings-growth ratio of 1.51 and a beta of 0.30.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.15. The company had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. Haemonetics’s revenue was down 5.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, sell-side analysts forecast that Haemonetics will post 4.55 earnings per share for the current year.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its stake in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 165 shares during the period. Quarry LP grew its stake in Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares in the last quarter. UMB Bank n.a. increased its holdings in Haemonetics by 91.7% during the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock worth $50,000 after purchasing an additional 320 shares during the period. Finally, Versant Capital Management Inc increased its holdings in Haemonetics by 216.4% during the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 567 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.